In-vitro evaluation of Sen 34343: antimicrobial activity, -lactamase stability and inhibition
- 1 January 1985
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 15 (suppl C) , 99-109
- https://doi.org/10.1093/jac/15.suppl_c.99
Abstract
Sch 34343 was compared with representative parenteral β -lactams including monobactams (aztreonam), I-oxa- β -lactams (latamoxef), carbapenems (imipenem) and cephalosporins (cefamandole, cefoperazone, cefotaxime, cefsulodin and ceftazidime). Sch 34343 was active against the Enterobacteriaceae (MIC50 range, 0.12–4.0 mg/1) and the facultative Gram-positive cocci (MIC50 range, 0.03–4.0 mg/1), and was comparable to the third-generation cephalosporins and imipenem. Pseudomonas aeruginosa and other Pseudomonas spp. were not susceptible to Sch 34343. Haemophilus influenzae and Neisseria spp. were all susceptible to ≤ 2.0 mg/1 of Sch 34343. Methicillin-resistant staphylococci (MIC 90 , 32 mg/1) appear to be insusceptible to Sch 34343. Sch 34343 inhibited the majority of cefotaxime- and gentamicin-resistant bacteria (MICs ≤ 8.0 mg/1). The new penem was stable to hydrolysis by 11 β -lactamase preparations (both plasmid- and chromosomsally-mcdiatcd types). Sch 34343 inhibited β -lactamases as did other newer cephalosporins.Keywords
This publication has 0 references indexed in Scilit: